Activity of polymyxin B combined with cefepime-avibactam against the biofilms of polymyxin B-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae in in vitro and in vivo models

• Published in: BMC microbiology Vol. 24; no. 1; pp. 409 - 13
• Main Authors: Tian, Miaomei, Yan, Bingqian, Jiang, Rong, Liu, Candi, Li, You, Xu, Bing, Guo, Siwei, Li, Xin
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 16.10.2024; BioMed Central; BMC
• Subjects: Animals; Anti-Bacterial Agents - pharmacology; Azabicyclo Compounds - pharmacology; Biofilm; Biofilms - drug effects; Cefepime - pharmacology; Cefepime-avibactam; Control; Disease Models, Animal; Dosage and administration; Drug Combinations; Drug Resistance, Bacterial; Drug therapy; Drug therapy, Combination; Klebsiella infections; Klebsiella Infections - drug therapy; Klebsiella Infections - microbiology; Klebsiella pneumoniae; Klebsiella pneumoniae - drug effects; Microbial mats; Microbial Sensitivity Tests; Moths - microbiology; Polymyxin B; Polymyxin B - pharmacology; Polymyxin B-resistance; Pseudomonas aeruginosa; Pseudomonas aeruginosa - drug effects; Pseudomonas aeruginosa infections; Pseudomonas Infections - drug therapy; Pseudomonas Infections - microbiology; Testing; China; Biofilm; Pseudomonas aeruginosa; Polymyxin B-resistance; Cefepime-avibactam; Klebsiella pneumoniae
• ISSN: 1471-2180; 1471-2180
• DOI: 10.1186/s12866-024-03571-3

Bacterial biofilms, often forming on medical devices, can lead to treatment failure due to their increased antimicrobial resistance. Cefepime-avibactam (CFP-AVI) exhibits potent activities against Pseudomonas aeruginosa (P. aeruginosa) and Klebsiella pneumoniae (K. pneumoniae) when used with polymyxin B (PMB). However, its efficacy in biofilm-related infections is unknown. The present study aimed to evaluate the activity of PMB combined with CFP-AVI against the biofilms of PMB-resistant Gram-negative bacteria. Five K. pneumoniae strains and three P. aeruginosa strains known to be PMB-resistant and prone to biofilm formation were selected and evaluated. Antimicrobial susceptibility assays demonstrated that the minimal biofilm inhibitory and eradication concentrations of PMB and CFP-AVI for biofilms formed by the eight strains were significantly higher than the minimal inhibitory concentrations of the antibiotics for planktonic cells. The biofilm formation inhibition and eradication assays showed that PMB combined with CFP-AVI cannot only suppress the formation of biofilm but also effectively eradicate the preformed mature biofilms. In a modified in vitro pharmacokinetic/pharmacodynamic biofilm model, CFP-AVI monotherapy exhibited a bacteriostatic or effective activity against the biofilms of seven strains, whereas PMB monotherapy did not have any activity at 72 h. However, PMB combined with CFP-AVI demonstrated bactericidal activity against the biofilms of all strains at 72 h. In an in vivo Galleria mellonella infection model, the 7-day survival rates of larvae infected with biofilm implants of K. pneumoniae or P. aeruginosa were 0-6.7%, 40.0-63.3%, and 46.7-90.0%, respectively, for PMB alone, CFP-AVI alone, and PMB combined with CFP-AVI; the combination therapy increased the rate by 6.7-33.3% (P < 0.05, n = 6), compared to CFP-AVI monotherapy. It is concluded that PMB combined with CFP-AVI exhibits effective anti-biofilm activities against PMB-resistant K. pneumoniae and P. aeruginosa both in vitro and in vivo, and thus may be a promising therapeutic strategy to treat biofilm-related infections.